SK-HEP-1 is an immortal, human hepatic adenocarcinoma cell line that grows in adherent culture. This cell line is capable of forming tumors in immunocompromised mice. SK-HEP-1 cells in culture have been shown to produce fibronectin and functionally active alpha-1 protease inhibitor. In addition, they constitutively produce Interleukin-1.
This cell line was established in 1971 from the ascites fluids of a 52-year old Caucasian male with adenocarcinoma of the liver.
- Germain Trempe, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Jorgen Fogh, PhD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering
- Fogh J et al. (1977) One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. Journal of the National Cancer Institute 59: 221-226 (PubMed ID: 327080)
- Glasgow JE et al. (1984) Fibronectin synthesized by a human hepatoma cell line. Cancer Research 44: 3022-3028 (PubMed ID: 6327032)
- Wang L et al. (2012) A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Molecular Cancer Therapeutics 11: 864-872 (PubMed ID: 22351746)
An alternative hypothesis regarding the origin of the SK-HEP-1 cells was presented by Heffelfinger and colleagues, who claim that these cells do not display properties of hepatocytes and are of endothelial origin (PubMed ID: 1371504).
This cell line may be licensed nonexclusively for research or commercial purposes.
For internal research purposes by a commercial entity: Utilize MSK’s Express License, attached here. In order to streamline and expedite the licensing of select MSK cell lines, the terms of this non-exclusive license are non-negotiable. Please note: This license is only available for select cell lines, including this one.
To proceed, please download this contract, fill in all relevant fields, and email a scanned version to TRMOTDRTM@mskcc.org. Once this license has been executed by MSK, you will receive a signed copy and invoice, and can then place your order with ATCC.
For licensing requests for a commercial purpose: Contact MSK’s Tangible Materials team at TRMOTDRTM@mskcc.org.
For non-licensing requests from academic-research institutions: Contact Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody & Bioresource Core Facility, MSK, 646-888-2354, firstname.lastname@example.org.